Watching! Lots of information coming before EO2Q!
$Werewolf Therapeutics(HOWL.US$ Upcoming Milestones! Most if not all data of some sort is to be released before end of Q2!
WTX-124:
WTX-124:
•In the first half of 2024, Werewolf expects to present additional interim dose-escalation data from the monotherapy dose-escalation arm, nominate a recommended dose for expansion and initiate monotherapy dose expansion arms.
•Additionally, Werewolf continues to progress combination dose escalation cohorts of the Phase 1/1b clinical trial and plans to report initial clinical data from this arm in the first half of 2024.
WTX-330:
•Werewolf is progressing Study WTX-330x2101, its Phase 1, multi-center, open-label clinical trial evaluating WTX-330 as a monotherapy in patients with immunotherapy insensitive or resistant advanced or metastatic solid tumors or non-Hodgkin lymphoma. Werewolf plans to report initial data from the Phase 1 study in the second quarter of 2024.
Preclinical Portfolio: WTX-712 & WTX-518! These programs are currently progressing through IND-enabling work.
•Additionally, Werewolf continues to progress combination dose escalation cohorts of the Phase 1/1b clinical trial and plans to report initial clinical data from this arm in the first half of 2024.
WTX-330:
•Werewolf is progressing Study WTX-330x2101, its Phase 1, multi-center, open-label clinical trial evaluating WTX-330 as a monotherapy in patients with immunotherapy insensitive or resistant advanced or metastatic solid tumors or non-Hodgkin lymphoma. Werewolf plans to report initial data from the Phase 1 study in the second quarter of 2024.
Preclinical Portfolio: WTX-712 & WTX-518! These programs are currently progressing through IND-enabling work.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
BelleWeather : I’ve also got this one on my watchlist:)
TrytosaveabitOP BelleWeather: Fantastic! I hope you’re having a great and restful weekend! Back to account building tomorrow! GL!